Table 1 Baseline characteristics of the included patients
|  | Empagliflozin (n = 52) | Placebo (n = 53) |
|---|---|---|
Age, yrs | 65.4 ± 11.1 | 64.1 ± 9.9 |
Males | 36 (69.2) | 36 (67.9) |
Systolic blood pressure, mm Hg | 132.8 ± 15.2 | 133.0 ± 14.5 |
Diastolic blood pressure, mm Hg | 76.4 ± 11.5 | 74.9 ± 9.5 |
Body mass index, kg/m2 | 26.2 ± 5.1 | 26. 9 ± 5.5 |
Hemoglobin, g/dL | 14.0 ± 1.6 | 13.7 ± 1.5 |
Hematocrit, % | 41.6 ± 4.6 | 41.3 ± 4.2 |
Uric acid, mg/dL | 5.7 ± 1.4 | 5.3 ± 1.1 |
Diabetes duration, yrs | 13.6 ± 13.2 | 13.0 ± 8.3 |
Fasting plasma glucose, mg/dL | 141.4 ± 25.0 | 146.4 ± 34.8 |
Glycohemoglobin, % (mmol/mol) | 7.2 ± 0.8 (55 ± 9) | 7.2 ± 0.9 (55 ± 10) |
eGFR, mL/min/1.73m2 | 67.0 ± 12.5 | 69.2 ± 13.9 |
UACR, mg/g·Cre | 32.0 (8.0 to 65.0) | 15.3 (7.5 to 41.5) |
NT-proBNP, pg/mL | 63.0 (31.0 to 180.0) | 80.5 (20.0 to 122.0) |
High-sensitivity troponin I, pg/mL | 3.2 (2.3 to 6.3) | 4.1 (2.2 to 8.1) |
Past medical history | ||
 Hypertension | 41 (78.8) | 36 (67.9) |
 Dyslipidemia | 39 (75.0) | 38 (71.7) |
 Heart failure | 23 (44.2) | 19 (35.8) |
 Myocardial infarction | 12 (23.1) | 13 (24.5) |
Treatment | ||
 Metformin | 25 (48.1) | 28 (52.8) |
 Thiazolidinedione | 12 (23.1) | 13 (24.5) |
 DPP-4 inhibitor | 37 (71.2) | 36 (67.9) |
 ACE inhibitor or ARB | 31 (59.6) | 38 (71.7) |
 Beta-blocker | 19 (36.5) | 19 (35.8) |
 MRA | 9 (17.3) | 5 (9.4) |
 Diuretic | 8 (15.4) | 10 (18.9) |